Seaport Therapeutics, Inc. (SPTX) Stock Forecast
SPTX analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.67 / 5 from 9 analysts
- Price target
- $37.00 average of analyst targets
- Upside to target
- +107.5% from the latest close
- Next earnings
- November 2, 2026 EPS estimate $-0.58
- 52-week range
- $15.25 – $27.84
SPTX analyst ratings
9 analystsNumber of analysts at each rating.
SPTX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
SPTX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.56 | −$0.63 | −$0.50 | — | — | 7 |
| Current fiscal year (2026) | −$5.59 | −$13.10 | −$3.76 | — | — | 7 |
| Next fiscal year (2027) | −$2.52 | −$2.99 | −$1.98 | −$5.59 | +54.9% | 7 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
SPTX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | — | 7 |
| Current fiscal year (2026) | $0 | $0 | $0 | — | 7 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 8 |
SPTX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
SPTX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.57 | −$0.56 | −$0.57 | −$0.57 | −$0.56 | −1.8% | 2 up · 1 down |
| Current fiscal year (2026) | −$5.11 | −$6.24 | −$5.90 | −$5.90 | −$5.59 | +9.5% | 0 up · 3 down |
| Next fiscal year (2027) | −$2.47 | −$2.58 | −$2.57 | −$2.57 | −$2.52 | +2.2% | 1 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
SPTX earnings surprises
Reported EPS vs the consensus estimate for the last 2 quarters; SPTX beat in 0 of 2.
What analysts expect from SPTX
9 analysts cover Seaport Therapeutics; their consensus rating is strong buy (4.67 on a 1–5 scale, where 5 is a strong buy). The average price target is $37.00, 107.5% above the latest close of $17.83. Analysts expect earnings of −$5.59 per share for 2026. For 2027 the average estimate is −$2.52 per share. Seaport Therapeutics beat the EPS estimate in 0 of the last 2 quarters.
Related: SPTX income statement, SPTX key metrics, SPTX chart. See the SPTX stock overview for the latest quote and news.
SPTX forecast FAQ
What is Seaport Therapeutics's price target?
The average analyst price target for Seaport Therapeutics is $37.00, 107.5% above the latest close of $17.83.
Is Seaport Therapeutics a buy, hold or sell?
Of 9 analysts covering Seaport Therapeutics, 7 rate it a strong buy, 1 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Seaport Therapeutics's EPS forecast?
Analysts forecast −$5.59 per share for 2026 (range −$13.10 to −$3.76); for 2027 the estimate is −$2.52.
When does Seaport Therapeutics report earnings?
Seaport Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 2, 2026; the EPS estimate is $-0.58.
Does Seaport Therapeutics usually beat earnings estimates?
Seaport Therapeutics reported EPS at or above the analyst estimate in 0 of the last 2 quarters.